Results 221 to 230 of about 47,434 (363)

Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer

Therapeutic Advances in Medical Oncology
Background: Current patient selection for adjuvant chemotherapy (ACT) after curative surgery for stage II colon cancer (CC) is suboptimal, causing overtreatment of high-risk patients and undertreatment of low-risk patients.
Astrid Kramer, Marjolein J. E. Greuter, Suzanna J. Schraa, Geraldine R. Vink, Jillian Phallen, Victor E. Velculescu, Gerrit A. Meijer, Daan van den Broek, Miriam Koopman, Jeanine M. L. Roodhart, Remond J. A. Fijneman, Valesca P. Retèl, Veerle M. H. Coupé   +12 more
doaj   +1 more source

Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma

, 2017
Maria Schwaederlé, Sandip Pravin Patel, Hatim Husain, Megumi Ikeda, Richard B. Lanman, Kimberly C. Banks, AmirAli Talasaz, Lyudmila Bazhenova, Razelle Kurzrock   +8 more
openalex   +1 more source

P1.13-18 Exploring the Resistance Mechanism of Osimertinib and Monitoring the Treatment Response Using Plasma ctDNA in Chinese NSCLC Patients [PDF]

, 2018
Ying Shi, Puyuan Xing, Xiaowei Han, S. Wang, Y. Liu, Po-Wu Liu, J. Li, Leona Chang, Yue Guan, Z. Zhang, Dianna Wu, Jia Yao, Xin Yan   +12 more
openalex   +1 more source

Assessing the exercise‐related kinetics of circulating cell‐free DNA, circulating tumour DNA, DNase I activity and cytokines in patients with solid tumours: A pilot study

Experimental Physiology, EarlyView.
Abstract Circulating cell‐free DNA (cfDNA), circulating tumour DNA (ctDNA) and inflammatory cytokines have prognostic and predictive value in oncology. However, the effects of acute exercise on cfDNA levels are unknown. Here, we explore the kinetics of cfDNA, ctDNA and cytokines upon an incremental exercise test in a pilot cohort of cancer patients ...
Elmo W. I. Neuberger, Alexandra Brahmer, Tobias Ehlert, Suzan Botzenhardt, Alfonso De Falco, Birgit Enders, Patricia S. Hähnel, Achim Heintz, Carl C. Schimanski, Thomas Kindler, Perikles Simon   +10 more
wiley   +1 more source

P2.01-101 Dynamic Monitoring of Gene Alterations with ctDNA by NGS for EGFR Mutated Lung Adenocarcinoma Treated with Gefitinib in BENEFIT Study (CTONG 1405) [PDF]

, 2018
Jiaxin Duan, Sumeng Wang, Z. Wang, Hao Bai, Jun Zhao, Hongjun Gao, Yuxin Cheng, Jo‐Fan Wang   +7 more
openalex   +1 more source

Urothelial carcinoma: Perioperative considerations from top to bottom

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract Urothelial carcinoma is an aggressive entity that is associated with significant morbidity, but there have been major advances in both our understanding of and treatment options for patients with this disease. In this review, the authors focus on novel therapeutic and diagnostic approaches in the perioperative setting, with an emphasis on ...
Wesley Yip, Salvador Jaime‐Casas, Anjaney Kothari, Mary Sullivan, Leslie K. Ballas, Domenique Escobar, Anne K. Schuckman, Jonathan E. Rosenberg, Jonathan A. Coleman   +8 more
wiley   +1 more source

147P Clinical testing of ctDNA from NSCLC patients using A 17-gene liquid biopsy mutation panel [PDF]

, 2018
DA Eberhard, John P. Bennett, Deborah Davison, Constance Hammond, Aaron Petty, J. Pluenneke, Andrew Dei Rossi, Gregory E. Alexander, D. Paragas, Margarita Lopatin   +9 more
openalex   +1 more source

MXene‐Based Electrochemiluminescence (ECL) Biosensors: A Review on Analyte Detection and Diagnostic Applications

MedComm – Biomaterials and Applications, Volume 4, Issue 4, December 2025.
This review highlights recent advances in MXene‐based electrochemiluminescence (ECL) biosensors, showcasing their exceptional sensitivity and versatility in detecting biomolecules, pathogens, and environmental pollutants. The integration of MXenes significantly enhances ECL signal amplification, paving the way for next‐generation diagnostic and ...
Kai Zhang
wiley   +1 more source

Clinical validation and utility of InVision ctDNA in advanced non-small cell lung cancer (NSCLC) patients [PDF]

, 2018
Jordi Remón, Laura Mezquita, David Planchard, Cécile Jovelet, Ludovic Lacroix, Étienne Rouleau, Karen Howarth, Vincent Plagnol, C. Morris, E. Green, C. Le Péchoux, Caroline Caramella, Julien Adam, Benjamin Besse   +13 more
openalex   +1 more source

Optimizing management of stage IV EGFR mutant non‐small cell lung cancer in Asia: An expert opinion

International Journal of Cancer, Volume 157, Issue 8, Page 1648-1661, 15 October 2025.
What's New? Emerging strategies for the treatment of advanced non‐small cell lung cancer (NSCLC) featuring epidermal growth factor receptor (EGFR) mutations are helping improve patient outcomes. Which strategies are optimal to effectively manage EGFR‐mutant NSCLC, however, remains unclear.
Gee‐Chen Chang, Akhil Kapoor, Chee Khoon Lee, Chunxia Su, Daniel Chan, Guia Elena Imelda Ladrera, Hye Ryun Kim, Mostafa Aziz Sumon, Moushumi Suryavanshi, Sita Andarini, Tatsuya Yoshida, Thanyanan Reungwetwattana, Tuan Khoi Nguyen, Pei Jye Voon   +13 more
wiley   +1 more source